Press Releases

11/29/2018

New Studies Using CELLSEARCH Circulating Tumor Cell Test to be Featured at San Antonio Breast Cancer Symposium

Research Adds to Growing Evidence of Clinical Utility of CTCs for the management of Metastatic Breast Cancer Patients

continue →

Topics: CELLSEARCH, CTCs, Precision Medicine, metastatic breast cancer, Liquid biopsy

03/12/2018

A robust method to study cancer heterogeneity in liquid biopsy

Copy Number Alteration Profiling of Single Circulating Tumor Cells which May Be used to Predict Response to Therapy

continue →

Topics: Liquid biopsy, CTCs, Precision Medicine, low-pass, copy number alteration, CELLSEARCH, DEPArray NxT, NGS

05/16/2017

Top International Experts Gather to Understand the Many Faces of Cancer

Second World Summit on Cancer Heterogeneity and Precision Medicine Meets in Washington

continue →

Topics: Cancer Heterogeneity, Liquid biopsy, CTCs, FFPE, International experts, International conference, Menarini International Foundation, Precision Medicine

04/3/2017

Menarini-Silicon Biosystems Completes Acquisition of CELLSEARCH® Assets

Liquid Biopsy Test for Circulating Tumor Cells Marks Its First Entry into U.S. Diagnostics Market

continue →

Topics: CELLSEARCH, acquisition, CTC test, CTCs, Liquid biopsy, deparray

12/20/2016

Menarini-Silicon Biosystems to Acquire CELLSEARCH® CTC System

Only FDA-Cleared CTC test to join Company’s Portfolio of Diagnostics

continue →

Topics: CTCs, CELLSEARCH, deparray, single-cell isolation

11/25/2016

DEPArray™ Single-Cell Isolation Technology Enables Researchers to Develop a Model for Predicting Response to Treatment in Patients with Lung Cancer

Genetic Profiles of Circulating Tumor Cells May Predict Drug Resistance and Clinical Outcomes

continue →

Topics: CTCs, lung cancer, deparray, SCLC

Ask Us a QuestionShare your DEPArray™ storySubscribe to newsletter